Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid

• Verfasst von: Wessels, Frederik [VerfasserIn]
• Verfasst von: Kriegmair, Maximilian [VerfasserIn]
• Verfasst von: Oehme, Alexander H. F. [VerfasserIn]
• Verfasst von: Rassweiler-Seyfried, Marie-Claire [VerfasserIn]
• Verfasst von: Erben, Philipp [VerfasserIn]
• Verfasst von: Oberneder, Ralph [VerfasserIn]
• Verfasst von: Kriegmair, Martin [VerfasserIn]
• Verfasst von: Ritter, Manuel [VerfasserIn]
• Verfasst von: Michel, Maurice Stephan [VerfasserIn]
• Verfasst von: Honeck, Patrick [VerfasserIn]
• Titel: Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid
• Verf.angabe: F. Wessels, M.C. Kriegmair, A. Oehme, M.C. Rassweiler-Seyfried, P. Erben, R. Oberneder, M. Kriegmair, M. Ritter, M.S. Michel, P. Honeck
• E-Jahr: 2019
• Jahr: 22 February 2019
• Umfang: 6 S.
• Fussnoten: Gesehen am 29.01.2021
• Titel Quelle: Enthalten in: European journal of surgical oncology
• Ort Quelle: Burlington, Mass. : Harcourt, 1995
• Jahr Quelle: 2019
• Band/Heft Quelle: 45(2019), 7, Seite 1260-1265
• ISSN Quelle: 1532-2157
• DOI: doi:10.1016/j.ejso.2019.02.023
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Acetylsalicylic acid
• Sach-SW: Antiplatelet
• Sach-SW: Aspirin
• Sach-SW: Bladder cancer
• Sach-SW: Cystectomy
• Sach-SW: Transfusion
• K10plus-PPN: 1746031204

Abstract

Introduction - Aim of this study was to analyse the perioperative outcome of patients undergoing radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid. - Materials and methods - Using prospectively maintained databases of two departments of urology, we identified 461 consecutive patients who underwent radical cystectomy for bladder cancer (2011-2017). Patients were divided into three groups: 1) on-going antiplatelet therapy with acetylsalicylic acid (n=50), 2) discontinuing antiplatelet therapy (n=65) and 3) no antiplatelet therapy (n=346). Perioperative outcome was compared between the three groups using ANOVA, likelihood ratio or Kruskal Wallis test with post-hoc testing. Uni- and multivariate analyses were performed to identify predictor for perioperative complications and transfusion. - Results - Group 1 showed an average estimated blood loss of 732±424, group 2 752±488 and group 3 810±544ml (p=0.51). There was no significant difference in transfusion rate (44% in group 1, 45% and 39% in groups 2 and 3, p=0.63). Severe complications occurred in 26%, 15% and 15% in groups 1-3 (p=0.19). Ischemic complications were more often observed in group 1 (n=4, 8%) and 2 (n=5, 8%) than group 3 (n=7, 2%), p=0.02. 90-day readmission (n=99, 22%) and mortality rate (n=10, 2.2%) were low and did not show any significant differences between the groups. In uni- and multivariate analysis ongoing therapy with acetylsalicylic acid was no independent risk factor for transfusion or severe complications. - Conclusion - Perioperative continuation of therapy with acetylsalicylic acid in radical cystectomy is safe with no difference in intraoperative blood loss, transfusion rate, complications or mortality.